FLUDEOXYGLUCOSE
Low Grade Glioma
Thomas HopeSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Low Grade Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tazemetostat National Cancer Institute (NCI) | Phase 2 | B |
FET Thomas Hope | Phase 2 | B |
Olaparib National Cancer Institute (NCI) | Phase 2 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2 | CCC |
Pamiparib University of California, San Francisco | Phase 1 | CC |
Same molecule, other indications
FLUDEOXYGLUCOSE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →